Public Companies
Compass Pathways’ Cash Holdings Grow Despite Heavy Spending on Horizon
Net losses for the company rose due to R&D costs.
The post Compass Pathways’ Cash Holdings Grow Despite Heavy Spending on Horizon appeared first…
Compass Pathways (Nasdaq: CMPS) reported a steady second quarter for 2023. The company is conducting phase 3 trials of its primary product, COMP360, a psychedelic therapy being developed to address treatment-resistant depression. The trials are said to be moving ahead according to plan.
During the quarter, the American Medical Association started accepting a new billing code that fits with the kind of support services COMP360 needs to conduct in-person psychedelic therapy support services, which could expand access as insurers will be able to help with the cost of treatment to widen access.
In a statement, CEO Kabir Nath also said that the FDA’s recently issued guidance on psychedelic drug development “represents an important validation of our area of science.”
The company said it held $148.2 million in cash and equivalents, an increase from $143.2 million at the end of 2022. The rise was helped by a secured term loan facility of up to $50 million, as well as sales of equity.
Despite a net loss of $28.3 million for the second quarter, an increase from the $21 million loss during the same period in 2022, Nath remains optimistic about the company’s progress. The losses were attributed largely to rising research and development costs, a necessary investment for COMP360.
“The cash received from the draw down from our debt facility with Hercules and sales of equity through our (at-the-market) program lengthened our cash runway significantly and allows us to continue to invest in our COMP360 development programs at full speed,” Nath said.
Compass is also exploring additional uses for COMP360, with ongoing phase 2 trials in anorexia nervosa and post-traumatic stress disorder. Additionally, the company mentioned that results from an investigator-led study on the use of COMP360 in female anorexia patients were recently published in the Nature Medicine journal.
The company anticipates spending between $80 million to $90 million in operational activities for the full year of 2023.
The post Compass Pathways’ Cash Holdings Grow Despite Heavy Spending on Horizon appeared first on Green Market Report.
psychedelic nasdaq invest compass fda research-
Law & Regulation6 days ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Psilocybin1 week ago
The Psychedelic Scene in Oaxaca, Mexico
-
Psychedelics1 week ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics1 week ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance
-
Psychedelics1 week ago
Lophos Pharmaceuticals Corp. Enters Into Letter of Intent to Acquire the Assets of Magicactus.com
-
Psychedelics1 week ago
Lophos Pharmaceuticals Corp. Enters Into Letter of Intent to Acquire the Assets of Magicactus.com
-
Psilocybin1 week ago
Oregon authorities give Kaya Holdings license for psilocybin treatment clinic